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Abstract
Objective: We sought to estimate visceral leishmaniasis (VL) burden in Bangladesh, India, and Nepal and document care-
seeking behaviour for VL to provide baseline information for monitoring the VL elimination program and identify options
for improved case finding and management.
Design: A cross-sectional study using cluster sampling (clusters being villages) of 4 VL endemic districts was used in order to
document all current and existing VL cases over the preceding 12 mo. Extended (in-depth) interviews were conducted in a
subsample of households to explore (a) VL-related knowledge, attitudes, and practices of the population; (b) use of VL care
by patients; and (c) delay between onset of symptoms, diagnosis, and start of treatment, as well as treatment interruption.
Findings were discussed with national program managers and policy makers to develop improved strategies.
Results: Screening for VL was done in 18,933 households (106,425 inhabitants). The estimated annual incidence of VL in the
endemic districts was on average 22 times higher than the elimination target of less than one case per 10,000 inhabitants in
2015. This incidence varied widely between study sites, from 9.0 to 29.8 per 10,000 inhabitants. The percentage of newly
detected cases through the household screening was high in the districts least covered by health-care services (particularly
Rajshahi, Bangladesh, 49%; and to a lesser extent Vaishali in Bihar, India, 32.5%), and much lower in districts with greater
availability of VL care (Muzaffarpur, India, 3.8%). On average 267 houses had to be visited, i.e., at least three to four working
days per health worker, to identify a new VL (ranging from 1,432 houses in Muzaffarpur, India to only 166 houses in Rajshahi,
Bangladesh). Knowledge of the disease and its vectors was good in India and Nepal but poor in Bangladesh (Rajshahi)
where very little attention has been given to VL over the last decades. Although all socio-demographic indicators showed
high levels of poverty, people in India preferred private medical practitioners for the treatment of VL, whereas in Nepal, and
even more in Bangladesh, the public health-care sector was preferred. Delays between onset of symptoms and diagnosis as
well as start of treatment was high. Reported non-adherence to treatment was particularly high in the more under-served
districts and was mainly due to lack of resources.
Discussion: The findings suggest that (a) house-to-house screening may be useful in highly endemic districts with a poor
passive case detection system, but further evidence on case finding adapted to local conditions has to be collected; (b)
strengthening the quality of the public health sector is imperative in the three countries, especially in India, with its largely
unregulated private-sector provision of VL care.
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Introduction
Visceral leishmaniasis (VL) is of major public health importance
in Bangladesh, India, and Nepal, affecting the poorest population
groups, primarily in rural areas. More than 60% of the world’s VL
cases are reported from these three countries and an estimated 150
million people are at risk of VL in 109 districts [1]. The region
reports 40,000 or more cases per year [1–4] but these official
figures are likely to underestimate grossly the real burden of VL in
the region [5,6] which results in an estimated loss of 400,000
disability-adjusted life years (DALYs) annually [7].
Until recently, diagnosis and treatment of VL posed a challenge
in endemic areas, because the diagnosis of VL required
demonstration of the parasite in tissue aspirates of spleen, bone
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marrow, liver, or lymph node. These invasive diagnostic
procedures were associated with a risk of severe complications
such as haemorrhage and death [8]. In contrast, the rK39 dipstick
test, with a sensitivity of 97% to 100% and a specificity of 86% to
92%, was found to be accurate and reliable for diagnosis when
used in combination with a clinical case definition [9–12], and has
been adopted by the VL elimination program; this initiative was
launched by the three countries in 2005 with the target of reducing
the annual VL incidence to less than one case per 10,000
population. For more than 60 y, VL treatment in the region
consisted of injectable drugs such as the antimonial sodium
stibogluconate (SAG), with decreasing cure rates. Recently, several
therapeutic alternatives have become available: a recently
registered oral VL drug, hexadecylphosphocholine (International
Nonproprietary Name: miltefosine), the injectable paromomycin,
and liposomal amphotericin B [13–16]. The VL elimination
program has recommended the use of miltefosine until an effective
combination therapy is available [17]. At the time of the study,
miltefosine was available only in India, while Nepal and
Bangladesh continued with antimonial treatment [18].
Further to these diagnostic and therapeutic breakthroughs, three
unusual features of VL in Southeast Asia make the disease
susceptible for elimination: humans are the only reservoir
(anthroponotic transmission); only one vector species transmits
the disease (Phlebotomus argentipes), whose abundance has been
drastically reduced as a side effect of the World Health
Organization (WHO) Malaria Eradication Programme; and the
geographic distribution of the disease is limited to 109 districts, with
more than 50% of VL cases occurring in the border districts of
Bangladesh, India, and Nepal. Additionally, there is a strong
political and administrative commitment in the three countries to
eliminate VL by 2015 or earlier [2], reducing the annual VL
incidence below one per ten thousand population; the governments
of the three countries signed a memorandum of understanding in
2005 and are supported by WHO in this goal [18].
However, several hurdles have still to be overcome to make this
target a realistic goal, and many are related to a lack of
information: no sound data about VL incidence in the region
exist [5]; little information about people’s access to and use of
diagnostic and treatment services in the public and private sector is
available; and information about adherence patterns linked to a
suspected lack of knowledge about the disease is limited to
speculation. This information is of vital importance for designing
appropriate and locally adapted VL elimination strategies.
Moreover, the current approach to VL in the region is based on
‘‘passive case detection,’’ i.e., patients are treated if they present
themselves to a health care provider. Given the low uptake of
health services in this region, the overall effectiveness of the VL
elimination program would be maximized were case detection
organized in a more active manner, by tailoring case management
approaches to local needs and addressing the issues of health
services weaknesses and management constraints.
In summary, quality baseline data that will allow for comprehen-
sive monitoring and evaluation of the progress and impact of the VL
elimination program in India, Bangladesh, and Nepal are scarce.
Hence, the present study was designed with the support of TDR/
WHO to (a) evaluate the current caseload of VL and compare it with
the elimination target, (b) describe people’s health-seeking behaviour
regarding diagnostic and treatment services and identify options for
improvement, and (c) explore the potential for active case finding
and community-based treatment strategies. This paper presents the
joint analysis of data collected in four distinct study sites in three
countries in order to identify similarities and differences in findings
and discuss the main implications for the VL elimination initiative.
Materials and Methods
Study Sites
Districts with high VL endemicity in Bangladesh, India, and
Nepal were identified, and, in each, subdistricts with consistently
high reporting of VL cases over the preceding 3 y (reported annual
incidence rates) were selected. The study districts included:
Rajshahi district in Bangladesh; Vaishali and Muzaffarpur districts
in Bihar State, India; and Mahottari district in South Nepal.
At the time of the study Vaishali (India) had few ongoing VL-
related control activities for the last decades. Muzaffarpur (India) is
known for a very active NGO (Kala-azar Medical Research
Centre) doing clinical research and serving VL patients through a
renowned private clinic for more than two decades. Mahottari
district (Nepal) has received a United States Agency for
International Development (USAID) grant in 2002–2003 for VL
control, with training of health workers and village volunteers and
VL awareness campaigns; there were also occasional VL-related
research activities. Rajshahi district (Bangladesh) has received very
little government attention so far and no external resources
regarding its VL problem. No VL research has been conducted so
far. When comparing the four study districts, Muzaffarpur and
Mahottari were better off due to substantial support from national
and international organizations; Rajshahi and Vaishali did not
receive such additional resources and can be characterized as
‘‘neglected districts.’’
Sample Size for Estimating VL Case Load
For the estimation of VL case load, we used an approximation
of the annual incidence rate (IR) (approximated by the number of
current VL cases plus cases reported by the households that started
treatment in the preceding 12 mo). We based the sample size
calculation on an assumed IR of 0.10% and a desired precision of
60.04% (95% confidence interval [CI]). Assuming a design effect
of 2, the final sample size per site was 21,096.
In a subsample of households (HHs), selected by systematic
sampling (Figure 1), an additional questionnaire was applied to
determine people’s knowledge and practices related to VL and
attitudes to different health-care providers for VL treatment.
Sample size calculation for this extended (in-depth) interview
survey was based on the assumption that only 5% of HHs (with a
required precision of 63%, 95% CI) would consult doctors
working in the public health services; the required sample size was
456 HHs. The same extended questionnaire was also applied in all
households in which a past VL case was identified through the
screening questionnaire.
Sampling Procedure
The data were collected from September 2006 to March 2007
in villages randomly selected from the list of all villages in
purposively selected VL-endemic subdistricts described above
(Figure 1). Villages comprised roughly 100 to 1,000 houses, and all
HHs were included in the sample, except for Mahottari, Nepal.
There, a subsample of HHs within villages had to be taken because
of security reasons (Figure 1). The study subjects were screened
with the aim of identifying all past and current VL patients who
were either currently on treatment or had been diagnosed within
the last 1 y. HH members were screened clinically and biologically
(see below) for VL. In a subsample of the houses screened and in
houses with new or recent (12 mo period) VL cases an extended
questionnaire was applied (‘‘in-depth interview,’’ Figure 1), with
the exception of Mahottari, where all households selected for the
screening were also asked to participate in the extended interview.
Visceral Leishmaniasis in the Indian Sub-Continent
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Survey Instruments and Organization of the Screening
Survey and In-Depth Interviews
Questionnaires. The questionnaire of the screening survey
was less than one page long and requested household
identification, educational level, and occupation of the head of
household. For all individual household members, the following
information was collected: name, age, gender, and if they had
fever during the last fortnight, if VL had been diagnosed during
the preceding 12 mo and if so, in which month. Interviewees with
fever were checked for an enlarged spleen and an rK39 dipstick
test was done. If positive the in-depth interview was conducted and
the suspected case (definition below) was referred (see below). The
in-depth interview was also done with household members who
had suffered from VL during the last 12 mo. This questionnaire
was longer and contained sets of questions about people’s
knowledge and practice regarding the disease, diagnosis and
treatment details, and time frames for each. The screening
questionnaire generally lasted 10 min and the in-depth interview
(45 questions) lasted 40 min.
Field staff. At each site four to six teams with two research
assistants or field health workers (seven field staff at both Indian
sites, eight in Nepal; eight in Bangladesh plus one experienced
supervisor in each site), most of them with previous field survey
experience, were recruited and trained. The study design and the
questionnaire were explained in detail and the assistants did a
number of test interviews, which were checked by the research
team. Finally, intensive training was provided on spleen
examination and conducting rK39 dipstick tests.
Survey procedures. Field staff conducted house-to-house
visits including all HHs in the selected villages and generally
applied the screening questionnaire to the heads of HHs. If they
identified a HH member with fever for 2 wk or more, they
performed a spleen palpation and rK39 dipstick test
(KalazarDetect) according to the manufacturer’s instructions
(InBios International, USA). If the test was positive, the
suspected VL patient was sent to the hospital together with a
case report form) for further examination, particularly spleen or
bone marrow aspiration. The case report form was later collected
by the research team. The research assistants also conducted the
in-depth interviews in a systematic sample (Figure 1) and in HHs
where they identified past and present VL cases.
Clinical Definitions and Treatment Strategy
A person with fever of more than 2 wk duration and
splenomegaly was defined as a ‘‘suspect VL case’’; a suspect case
who was rK39 positive was defined as ‘‘probable VL case.’’ A
‘‘confirmed VL case’’ was a suspect case with a splenic or bone
marrow aspiration positive for Leishmania donovani parasites. The
analysis presented in this paper is based on all probable cases,
because (a) in the three countries it is current practice to treat
rK39-positive cases, (b) a number of probable cases identified by
household screening in this study sought treatment in the private
sector or refused any invasive diagnosis, and (c) at one site
(Bangladesh) parasitological diagnosis is not done by health
services at the subdistrict level. The sum of the newly detected
cases by house-to-house screening and the reported cases
diagnosed during the preceding 12 mo was defined as ‘‘annual
VL incidence estimate’’ for highly endemic districts. VL deaths
during the previous 12 mo were not taken into account, because
cause-of-death reporting was unreliable.
Supervision and Quality Control of Interviewers
Quality control of data collection was done through a check of
all completed interviews and by a repeat of 10% of the interviews
Figure 1. Study population and sampling. Districts and subdistricts were selected purposefully based on consistently high numbers of case
reports. Villages were identified through one-stage cluster sampling (random selection of villages from a list of all villages); the screening survey
covered all HHs of the selected villages. HHs for in-depth interviews were selected by systematic sampling of screening HHs. In Nepal, because of
security concerns a randomly selected sample of HHs was interviewed in the study villages and the in-depth interview was applied to all of them.
*The smallest administrative unit in India and Nepal is Panchyat and Village Development Committee (VDC), respectively, which frequently includes
one large village and occasionally an agglomeration of smaller villages (labelled in the diagram as ‘‘village’’). Primary Health Care Centres (PHC) serve
a subdistrict, while the entire district is served by a district hospital.
doi:10.1371/journal.pntd.0000355.g001
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by field supervisors who asked only the core questions again. Fever
history, spleen enlargement, and rK39 tests were repeated in
referral centres, but not all detected patients went there (see
below). Additionally, an external monitor visited the four field sites
in the three countries to ensure a standardized application of the
joint research protocol.
Ethical Considerations
Before the start of the project, the protocol received clearance
from the ethical committee at each study site and by the WHO
Ethical Review Committee. The study participants gave written
individual informed consent.
Data Management and Analysis
As soon as data were collected from each site and checked by
the supervisor, the completed questionnaires were submitted to the
data processing unit at each site, where all instruments were
verified manually for completeness, consistency, and manual
errors. In case of any inconsistency interviewers were sent to the
respective household to repeat the interview. After verification,
each record was given to two data entry operators for double data
entry. Data were entered in predesigned data entry program in
EpiInfo 3.2.2 and then sent electronically to the central data
management centre in Pune, India, where they were transferred to
SPSS. The joint data analysis was done by a professional
statistician at Banaras Hindu University (BHU), Varanasi, India.
Through cross checks the consistency of the data was rechecked
and cleaned. Finally, the data were analyzed in SPSS 10.0.
Descriptive statistics as well as Chi-square test for comparison
between proportions were performed. Quantitative data were
expressed as average6standard deviation (SD), and categorical
data as percentages with 95% CI, with online software from
Dimension Research [19]. All p-values were two tailed and a p-
value of #0.05 was taken as significant.
Results
Demographic and Socioeconomic Conditions (Screening
Survey)
Site-specific demographic and socioeconomic conditions are
shown in Table 1. A total of 18,933 households with 106,425
inhabitants were screened in the three countries (Table 2). The
proportion of males was higher in Vaishali and Muzzafarpur (India),
andMahottari (Nepal) compared to Rajshahi (Bangladesh) (Table 1).
The high level of poverty at all four study sites can be seen in the
following indicators: (a) Very young population; 34.05% (95% CI,
33.8%–34.3%) of the study population were children under 15 y. (b)
Crowded living conditions with 6.863.3 persons per household and
an average of 2.762.2 rooms per house. (c) Inadequate housing, with
79.1% (95% CI, 77.8%–80.4%) living in thatched houses with mud
plaster or made only with bamboo sticks. (d) High illiteracy rates;
with 47.4% (95%CI, 45.8%–49.0%) of household heads were
illiterate. (e) Low-paid work; 26.8% (95% CI, 25.4%–28.2%) of
heads of households were landless labourers or unskilled workers.
Looking at site-specific variation, there was little difference in the
large proportion of children in the total population (reflecting an
almost triangle-shaped population structure), but illiteracy and
crowding were particularly high in Mahottari (56.4% and 7.4
persons per HH respectively), inadequate housing was frequent in
Rajshahi (95.3%), and landless labourers and unskilled workers
predominated in Vaishali (40%). In Muzaffarpur the indicators
showed a slightly more favourable situation.
Estimated VL Case Load (Screening Survey)
The screening survey (Table 2) identified 364 persons in the total
study population with fever of more than 2 wk; 293 of these had a
negative rK39 and were referred to the hospital for further
diagnosis. Seventy-one of them (71/364, 19.5%) had splenomegaly
and a positive rK39 test and were therefore classified as ‘‘VL case,’’
Table 1. Demographic and socio-economic conditions.
Indicator Vaishali, India Muzaffarpur, India Mahottari, Nepal Rajshahi, Bangladesh p-Value
Screening survey
Total population 31,863 31,876 17,239 25,447 —
Population aged #15 y, % (95% CI) 42.00 (41.44–42.52) 33.8 (33.28–34.32) 39.70 (39.00–40.46) 37.80 (37.24–38.44) ,0.0001a
Male sex, % (95% CI) 53.20 (52.64–53.74) 53.91 (53.36–54.46) 54.0 (53.19–54.67) 50.50 (49.93–51.15) ,0.0001b
Average family size6SD 6.0163.17 5.6662.25 7.7065.87 4.561.84 ,0.0001c
Household survey n= 409 n= 482 n= 2336 n=556 —
Age of household head, mean6SD 40.38620.15 39.30616.38 46.89613.44 42.76612.52 ,0.001d
Household head with no education, % (95% CI) 45.23 (40.41–50.05) 41.29 (36.89–45.69) 56.38 54.37–58.39) 51.98 47.83–56.13) ,0.05e
HH head with unskilled/labour occupation, % (95% CI) 42.3(37.5–47.1) 38.8 (34.5–43.2) 20.21 18.6–21.8) 32.6 28.7–36.4) ,0.05f
Inadequate housing, % (95% CI) 85.82 (82.44–89.20) 54.36 (49.91–58.81) 76.97 (75.26–78.68) 95.32 (93.56–97.08) ,0.0001g
Number of rooms in house, mean (95% CI) 2.22 (2.09–2.34) 1.80 (1.70–1.90) 3.15 (3.05–3.25) 2.00 (1.89–2.10) ,0.05g
Persons per HH, mean6SD 6.363.6 6.362.6 7.463.4 4.962.1 ,0.0001h
aOnly Mahottari and Vaishali did not differ significantly.
bRajshahi differs significantly from other sites.
cEach site differs from other significantly.
dMahottari differs from all sites and Rajshahi differs from Mahottari and Muzzafarpur.
eNo significant difference between Rajshahi and Mahottari as well as between Vaishali and Muzzafarpur, but Rajshahi and Mahottari differed significantly from Vaishali
and Muzzafarpur.
fVaishali and Muzzafarpur do not differ significantly.
gEach site differs significantly from other.
hTwo sites of India did not differ significantly in-between them.
doi:10.1371/journal.pntd.0000355.t001
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strictly speaking as ‘‘probable VL case’’ to be treated according to
national guidelines. Additionally 166 VL cases were reported in the
interviews who had been diagnosed within 12 mo preceding the
interview and where the reported date of diagnosis was within that
12 mo period. Thus the average estimated annual VL incidence rate
in all study sites was 22.3 per 10,000 (237/106,425; 95% CI 20.0–
26.0). The proportion of cases detected through screening, out of all
cases identified in the 12 mo period (i.e., reported cases within
preceding 12 mo based on passive case detection [PCD], plus newly
detected cases through active case finding [ACF]) was 30.0%; this
proportion can be used as an indicator of the weakness of the passive
case finding system across study sites.
There were important site-specific differences (Table 2): The
highest estimated annual VL incidence rate was registered in India
(Vaishali) and Bangladesh (Rajshahi), and the lowest in Nepal
(Mahottari). The proportion of probable (rK39 positive) VL cases
out of patients with fever was high in Vaishali, India (55.1%) but
only between 10% and 15% at the other three study sites.
The proportion of cases found through ACF out of all cases
identified was high in the more neglected districts such as Rajshahi,
Bangladesh (where 49.3% of cases were detected only through ACF)
and low in Muzaffarpur, India where case detection and treatment
through NGOs has a long tradition (only 5.8% case detection
through ACF); in districts with a reasonable PCD system including a
reasonable level of VL awareness in the population (see below) less
than half of all cases identified had been detected through ACF:
48.2% in Vaishali, India and 37.5% in Mahottari, Nepal. All rK39-
positive febrile patients with enlarged spleens were parasitologically
confirmed in Nepal, but only half of them in India, because many
patients preferred the private sector for treatment. Parasitological
diagnosis was not available in Bangladesh at the subdistrict level.
Effort to Detect New Cases through Active Case Finding
(Screening Survey)
On average 267 houses (18,933 houses/71 new VL cases) had to
be visited in VL endemic villages in order to identify one probable
case with prolonged fever, splenomegaly, and positive rK39 test,
which corresponded to at least three to four working days of a
trained interviewer or village health worker. As can be expected,
the lower the disease prevalence rate, the higher the screening
effort to find a new case. The number of houses to be screened was
highest in Muzaffarpur, India (1,432) and lowest in Rajshahi,
Bangladesh (166, Table 2).
Knowledge about VL (In-Depth Survey)
People’s knowledge about VL was poor in the neglected
districts, particularly Rajshahi, Bangladesh, compared to the
better served districts in India and Nepal: In India almost all
interviewees (98%; 873/891 combining Muzaffarpur and Vaishali)
were aware of kala-azar, the local term for VL. This was less in
Bangladesh (91%; 507/556) and Nepal (82%;1,915/2,336)). Fever
as the leading symptom was identified by 92% of interviewees in
India, but only by 72% in Nepal and 30% in Bangladesh. Ninety-
eight percent of the Indian and 97% of Nepali respondents knew
that VL is curable, but only 64% in Bangladesh were aware of this
(denominators as above). Likewise the knowledge about sand flies
(local term in questionnaire) transmitting the disease was frequent
in India (71%) and Nepal (88%) but rare in Bangladesh (21%).
Health-Seeking Behaviour (In-Depth Survey)
Across all sites local unqualified village health workers were
preferred as first-choice health care providers. This choice was
associated with their excellent accessibility (on average 15 min travel
time). Choosing health care beyond the community, the Indian
respondents preferred private providers over governmental ones
while in Bangladesh and Nepal public services were preferred over
the private ones (Figure 2). The choice between private or public
health care professionals was not dependent on travel times and
transport costs to private and public practitioners, because these
were similar in the study sites or, in Bangladesh, even longer/more
expensive to reach the preferred government doctors. Respondents
in India would use for the treatment of VL mainly the private sector
(50%) and less the public sector (30%), while in Nepal and
particularly in Bangladesh the pattern was the reverse: mainly use
of public sector (Nepal 45%; Bangladesh 52%) and less of private
practitioners (11% and 13%, respectively). Additionally, in India
people resorted to local unqualified village health workers for VL
treatment (12%), in Nepal to indigenous healers (23%), and in
Bangladesh to local chemists (28%). Main reasons for choice of
health care provider for VL treatment were: geographical
Table 2. VL epidemiological findings in study areas.
Indicator Vaishali, India Muzaffarpur, India Mahottari, Nepal Rajshahi, Bangladesh Total or Average
Population screened, n 31,863 31,876 17,239 25,447 106,425
Number of households screened, n 5,213 5,728 2,336 5,656 18,933
History of fever $2 wk, n 49 35 58 222 364
Positive rK39 test among febrile persons, n
(%, 95% CI)
27 (55, 41–69) 4 (11, 0.89–21) 6 (10, 2.5–18) 34 (15, 10.58–20) 71 (19.51, 15.41–23)
Reported past and current VL cases during
preceding 12 mo
56 65 10 35 166
Contribution of active case finding approach,
% (95% CI)a
32.53 (22.45–42.61) 5.8 b (0.28–11.32) 37.5 (13.78–61.20) 49.28 (37.48–61.08) 29.96 (24.13–35.79)
Estimated annual incidence of VL per 10,000
population (95% CI) c
29.8 (20–32) 22.0 (17–27) 9.0 (5–13) 27.0 (21–33) 22.7 (12–30)
Houses to be visited to find one new VL
case, nd
193 1,432 389 166 267
a(New cases/[new VL cases+past and current VL cases])6100.
bOnly Muzzafarpur differed significantly from all other sites.
c([Newly detected VL case+reported past and current VL cases]/total population)610,000.
dNumber of households screened/number of (suspected) VL cases.
doi:10.1371/journal.pntd.0000355.t002
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accessibility for village health workers, indigenous healers, and local
chemists; but for selecting between private and public sector the most
frequently mentioned factors were ‘‘faith’’ (belief that VL can be
treated adequately) and ‘‘good interpersonal communication.’’
The selection pattern between private and public health sector
for treatment of kala-azar was roughly confirmed by interview
answers of 113 current and past (,12 mo) VL patients in the in-
depth study (Figure 2; not all patients identified answered): In
India 80% (53/70) had used the private sector and 20% the public
sector. In Bangladesh the use of public sector was 81.2% (28/35).
Of the eight patients interviewed in Nepal, six (75.0%) went to the
public sector and two (25%) went to local chemists.
Delay in Diagnosis and Treatment (In-Depth Study of VL
Patients)
Delays of more than 2 wk (Figure 3) between onset of symptoms
(‘‘feeling ill’’) and seeking care was frequent (57.8% of the 113 VL
patients who responded) with the highest proportion in Rajshahi,
Bangladesh (65.7%). The delay between resorting to the health
care provider and receiving the diagnosis was 1 wk or less in most
cases (58.4%), but particularly long in Vaishali, India, because of
the outsourcing of diagnostic services from public hospitals and
health centres to private laboratories (58.8% with more than 4 wk
delay). There was significant delay between diagnosis and start of
treatment by more than 2 wk particularly in the neglected districts
of Vaishali and Rajshahi.
Treatment Interruption and Reasons (In-Depth Interview)
Of 113 VL patients, 22.8% interviewed reported having
interrupted the treatment at one stage. In most cases (85.7%)
the reported interruption was 2 wk or less; this was particularly the
case in Muzaffarpur, India and Mahottari, Nepal; however, in
Rajshahi, Bangladesh half of VL patients and in Vaishali, India,
one-third of patients had interrupted their treatment for more than
3 wk. Main reported reasons for treatment interruption were lack
of money for treatment (68.7%) and side effects (15.7%).
Discussion
Limitations of the Study
The four study sites in three countries illustrate the variety of
epidemiological, ecological, social, and health services conditions
Figure 2. Choice of health care provider beyond community level by 113 VL patients. * Informal doctors.
doi:10.1371/journal.pntd.0000355.g002
Figure 3. Reported treatment delay of more than 2 wk from onset of symptoms to diagnosis and start of treatment as a proportion
of 113 VL patients in India, Bangladesh, and Nepal.
doi:10.1371/journal.pntd.0000355.g003
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that shape VL transmission in the region. The information was
collected in highly endemic districts and cannot be extrapolated to
other areas. Furthermore, the large variation between sites
enriches the interpretation but also highlights the need for more
detailed site-specific analyses (unpublished data).
Explanatory Factors for Variation of Estimated VL
Incidence across Sites
Possible explanatory factors for the variation of VL incidence
(estimated VL incidence three times higher in Rajshahi,
Bangladesh compared to Mahottari, Nepal) include:
(a) Serious attempts at earlier case detection and treatment have
been made in Muzaffarpur, India and to a lesser extent in
Mahottari, Nepal. (PCD was considerably more successful in
Muzaffarpur with 94.2% of cases detected compared to
Rajshahi, Bangladesh with only 50.7% of cases detected
through PCD; delay between feeling sick and getting
treatment was particularly low in Muzaffarpur and high in
Rajshahi and Vaishali, India.)
(b) People’s exposure to VL-related health messages, particu-
larly in Muzaffarpur and less in Mahottari as compared to
Rajshahi has increased awareness about the disease and the
vectors (for example, awareness of fever as leading symptom
and mosquitoes as transmitting agents was high in
Muzaffarpur and low in Rajshahi) and—together with a
better availability of treatment facilities and drugs—has
possibly contributed to faster care seeking and better
adherence to treatment schedules.
(c) Vector control, although still insufficient and of questionable
quality in India and Nepal, seems to impact on the vector
population compared to Bangladesh where vector control has
largely been abandoned during the preceding decades [20,21].
Recognition of Study Results by the Regional Technical
Advisory Group
The study has provided important evidence to be considered in
designing the case detection/case management components of the
kala-azar (VL) elimination strategy. These points were discussed in
2007 and 2008 with RTAG (Regional Technical Advisory Group
for the Kala-azar Elimination programme), which includes key
stakeholders from Ministries of Health, academia, WHO/
SEARO, and donors (World Bank) in the three countries, and it
advises policy makers on the technical aspects of the elimination
strategy. The following findings were identified as being
particularly relevant and leading to action:
(a) The actual estimated annual VL incidence in the highly
endemic study districts is roughly 22 times higher than the
elimination target for 2015 (less than one per 10,000);
although not representative for all endemic areas, repeated
progress monitoring through screening surveys in sentinel
sites (‘‘indicator areas’’) of highly endemic districts using the
simple data collection tool of this study are recommended for
monitoring operational progress and health impact. The cost
and feasibility of such a monitoring system through the
public health sector should be assessed, and further districts
should be included to have a broader basis of baseline data
to allow for monitoring of progress.
(b) Active case finding in high-endemicity districts/subdistricts
through household screening for fever patients with
subsequent spleen palpation and rK39 testing and treatment
seems to be feasible (on average 272 households have to be
visited by a village health worker, which means between
three and four working days) but should be restricted to
districts where PCD is weak and thus the yield of ACF
detected cases can be expected to be high; further studies are
recommended about different models of ACF (house-to-
house screening, mobile clinics, incentives for detecting a
new case, index case–triggered screening) and about their
operational costs (cost per case detected) compared to
improved PCD. Active case finding could help not only to
shorten treatment delay by preventing ‘‘healer shopping’’
with an indiscriminate and expensive use of a large variety of
formal and non-formal health care providers [22–24], but
also to keep newly detected patients in the public sector;
however, evidence has to be collected to test this assumption.
(c) The easily accessible unqualified village health workers could
be (better) trained to spread important health messages and
eventually participate in the early provisional VL diagnosis
by alerting people with fever and facilitating the access to
rapid diagnosis.
(d) Outsourcing of VL diagnostic services in some parts of India
including the two study districts should be re-assessed,
because it contributes to a delay in diagnosis (as shown for
Vaishali district) and treatment.
(e) Special attention should be paid to the role of the private
health sector, particularly in India, because our study and
others [25,26] have documented high utilization of private
medical services with questionable VL treatment practices.
Likewise, the extensive use of local chemists in Nepal
(Figure 2) needs more attention. With the advent of oral
drugs the tendency for uncontrolled and inadequate drug
use may be increased, so a realistic policy response is
urgently needed for both India (private sector regulations)
and Nepal (monitoring of private pharmacies). VL treatment
is free of charge in the public hospitals of Bangladesh, India,
and Nepal. Nevertheless, in all three countries a realistic
assessment of health services performance and options for
improvement should be undertaken and alternative case
management strategies—such as DOT (directly observed
therapy), including monitoring of side effects and patient
satisfaction—should be developed and validated.
(f) ‘‘Information, education, communication’’ (IEC) campaigns,
particularly in Bangladesh, would be useful for improving
people’s knowledge about the disease and its prevention and
treatment, but costs and expected outcomes for such
campaigns should be established.
In view of the many barriers for reaching the elimination goal, a
massive effort in terms of up-scaling human resources, supplies,
logistics, and monitoring activities will be required. This study has
provided important baseline information necessary for monitoring
progress. Additional research in a second phase of studies, as
outlined above and to be designed jointly by the research teams and
VL country programme managers, will contribute to adapting the
elimination strategy to needs and identifying implementation plans
with a focus on cost effectiveness, safety, and final outcomes of VL
case finding and treatment through the primary health care system
with the back-up of hospitals. The RTAC highlighted the need for
continued interaction between researchers, national program
managers, and political decision makers. The main challenge for
the VL elimination initiative is to increase access to VL care in these
underserved areas; exploring active case finding also seems
worthwhile. Meanwhile, the main measure to attract patients to
the public health system would be to remove any financial barriers
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(fees for consulting, for investigations, for drugs, etc.) and to increase
quality of care. Additionally, regulation of the private sector should
be attempted to improve the quality of VL care.
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